+ AND 2 CYTOMEGALOVIRUS SUMMARY
FILE ID: 6013

NAME: VANILLIN-EP, LIEBMAN
NODEC: 3,7,10,16,23,29,35,37,38,41
SEAC: SECD APPROVED (08-02-84) 182P
TESTING STATUS: ACTIVE
DECISION TREE: 1
ISS: CORPORATE 199-16-93
CHEM ABSTRACTS NUMBER: 111-77-5
FDA IMPRETS: 211
PH. 7.4
MUTAGENICITY VEHICLE: DMSO
IP VEHICLE: SUSP. 1% MEH W/WON
ORAL VEHICLE: SUSP. 1% MEH W/WON
IV VEHICLE: ISOTONIC
SPECIAL INSTRUCTIONS: PREPARE I.N.C. SUSPENSIONS DAILY @ 0.25%/ML W/ PHOSPHENTATION
AMES/LC: NEG
UDSI: NEGATIVE
RLS: NEG
ACIDITY: IV - NEGATIVE
ACTOTX R1: ORAL LOOKING (KRI) MALES >(ECO)
ACTOTX R11: ORAL LTD/O/M/MSI MALES 35000
REPAIRS: ORAL MALES & FEMALES 50/MG
*NOTE: IP ORA L.L.D. (KRI) MALE & FEMALE S.L.T.O. LOOKING RESP. TO SEAC.
*NOTE: ORAL SUPPRESSION OF THE PRIMARY ANTIBODY RESPONSE TO SRBC.
*NOTE: ORAL SNB/R(KRI)-1000, 500, 250MG/KG-HOST RESISTANCE, NE, NEC, PFC ASSAY,NE, NE IN GENERAL, BODS DID NOT MODULATE THE IMM
UNE RESPONSE IN MICE. HOWEVER, SLIG INCREASED ABS & REL SPLEN WT AT 250 MG/KG SUGGEST A POTENTIAL FOR IMMUNOSTIMU-
LATION.
TERAT: ORAL DRAFT FINAL (PENDING SUMMARY BY MB)

81304258